CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about CRISPR Therapeutics AG (CRSP) before we discuss the ...

Stocks: Real-time U.S. stock quotes reflect trades reported through ... Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange ...

Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from ...

The latest trend in earnings estimate revisions for the stock doesn't suggest further ... CRISPR Therapeutics (NasdaqGM:CRSP) experienced an 12% price decline over the last week, coinciding ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) can’t seem to catch a break, now down close to 8% year to date and more than 80% ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

Viatris (NASDAQ:VTRS). Buy to sell by Edmund Ingham. "Despite some promising new products, the company's ability to grow ...

If an investor was to purchase shares of CRSP stock at the current price level of $38.20/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...